Preterm Birth Prevention and Management Market | Biophar Lifesciences Pvt. Ltd., Jasco Labs (P) Ltd., BSA Pharma Inc., Pfizer Inc | By 2029

The global Preterm Birth Prevention and Management Market is estimated to be worth around US$ 1.41 Billion in 2022. With increasing adoption of preterm birth prevention and management therapeutics across both developed and developing regions, the overall market is anticipated to grow at 10.1% CAGR between 2022 and 2029, totaling a valuation of US$ 2 .78 Billion by 2029.

The global Preterm Birth Prevention and Management Market surpassed the valuation of US$ 1 Billion in 2022, with growth projected to see a robust CAGR of more than 9% through 2029. The preterm birth prevention drugs industry is observing a substantial surge in number of FDA-approved new generic copies of blockbuster drugs every year. This can be primarily attributed to favourable government policy framework and demographics, orphan drug designations, adoption of new combination therapies, and complications in the selection of one line of therapy.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-6457

Key Takeaways of the Study

• Development of higher complexity specific portfolios and consistent focus on areas of strength while working pipelines are the cornerstone for success in the preterm birth prevention market space.
• Ensuring preterm interventions and research given proportional focus, so funding is aligned with health burden to curb the mortality rate
• Makena, with various approvals for the treatment of preterm birth in potential female patient pool, contributed to the dominance of the progesterone therapy segment by therapy type in 2018 and continue to do so during the forecast period.
• Highly effective therapies with cost advantage over are expected to generate significant revenue in the long run.
• Majority of the global preterm birth cases have not been directed towards preterm diagnostic leading to higher mortality rates and complications
• Sale of Hydroxyprogesterone over antihypertensive drugs such as Nifedipine, and labetalol in the global preterm birth prevention and management market has increased drastically owing to quicker onset of action and higher efficacy.

Launch of Cost-effective Therapies Bodes Well for Market

New revenue opportunities in developed economies, and orphan drug designation by FDA are contributing significantly towards the launch of cost-effective therapies. A few other factors assisting the growth of preterm birth prevention and management market include adoption of preterm diagnostic tests and the economic burden of premature birth on the system.

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-6457

Frequent drug shortages and unavailability of life-saving formulations in many parts of the country, growing initiatives by government and manufacturers for supply of life-saving preterm birth drugs, particularly in low income and developing countries, are driving the market growth.

More Valuable Insights on Preterm birth prevention and management Market

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the segments from 2014 to 2029. The global preterm birth prevention and management market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provide compelling insights on preterm birth prevention and management market on basis of therapy type (progesterone therapy, corticosteroid therapy, tocolytics therapy, antihypertensive therapy, magnesium sulfate therapy, heparin prophylaxis therapy, low-dose aspirin therapy, and antibiotics therapy) and by route of administration (Oral, Parenteral, and Vaginal) , and by patient type (prior spontaneous PTB, preeclampsia, short cervix, chronic hypertension, insulin-dependent, twins, antiphospholipid antibody syndrome, and others) and by distribution channel (hospital pharmacies, retail pharmacies, drug stores, and mail order pharmacies), across seven major regions.

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-6457

Market segmentation

By Therapy Type:

• Progesterone Therapy
• Corticosteroid Therapy
• Tocolytics Therapy
• Antihypertensive Therapy
• Magnesium Sulfate Therapy
• Heparin Prophylaxis Therapy
• Low-Dose Aspirin Therapy
• Antibiotics Therapy

By Route of Administration:

• Oral
• Parenteral
• Vaginal

By Patient Type:

• Prior Spontaneous PTB
• Preeclampsia
• Short Cervix
• Chronic Hypertension
• Insulin-dependent
• Twins
• Antiphospholipid Antibody Syndrome
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Mail Order Pharmacies

Use promo code >> FMITODAY to get flat 20% discount

By Region:

• North America
• Europe
• Latin America
• South Asia
• East Asia
• Oceania
• Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 08-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs